TABLE 4.
Blind (randomized) assay results
| Blinded (randomized) sample | Result for:
|
Sample source | |||
|---|---|---|---|---|---|
| Single-PCR assaya | Nested-PCR assayb | OR-QNRT-PCR assay (copies/ml CSF)c | WR-QNRT-PCR assay (copies/ml CSF)d | ||
| A | − | − | − | − | Cryptococcal meningitis (negative control) |
| B | + | + | + (2.5 × 105) | + (25,647) | Case 1 |
| C | − | + | + (8.6 × 104) | + (12,214) | Case 2 |
| D | − | − | − | − | Viral meningitis (negative control) |
| E | − | − | − | − | CNS lupus (negative control) |
| F | − | + | + (1.2 × 105) | + (18,236) | Case 3 |
| G | + | + | + (9.2 × 103) | + (9,542) | Case 8 |
| H | − | − | − | − | Viral meningitis (negative control) |
| I | − | − | − | − | Multiple sclerosis (negative control) |
| J | − | + | + (2.7 × 103) | + (8,705) | Case 9 |
a
Rate of consistency to previous assay results, 90%.
b
Rate of consistency to previous assay results, 100%.
c
Rate of consistency to previous assay results, 100%. Wilcoxon signed-rank test P value, 0.0052.
d
Rate of consistency to previous assay results, 100%. Wilcoxon signed-rank test P value, 0.147 (no significant difference).